Close Menu

NEW YORK – NantHealth reported after the close of the market Thursday that its fourth quarter revenues increased nearly 3 percent to $22.9 million from $22.3 million a year earlier.

The Culver City, California-based company posted a net loss of $49.1 million, or $.45 per share, compared to a net loss of $21.6 million, or $.20 per share, in Q4 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.